IBRX 8-K 2026-01-15

ImmunityBio, Inc. (IBRX) 8-K dated 2026-01-15 — accession 0001326110-26-000008. This URL is the filing, not the IBRX hub.

ImmunityBio, Inc. (IBRX) is a biotechnology company listed on US.

ImmunityBio, Inc. filed a 8-K on 2026-01-15. Accession 0001326110-26-000008.

Cached items: 2.02, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported IBRX revenue for 2026-06-30 was $51.2M. Net income was -$230.4M. Revenue was up 15.9% from 2026-03-31 to 2026-06-30. IBRX currently screens at market cap $7.88B.

Not investment advice. The IBRX SEC hub lists recent forms. The stock page is the research view.